Biotechs Target Cancer Metabolism

As reseachers uncover linkages between tumor formation and cellular metabolism, start-ups and their venture backers see an opportunity to create a new class of cancer medicines. In this issue, we profile Advanced Cancer Therapeutics, Cornerstone Pharmaceuticals and Dynamix Pharmaceuticals.

Over the past two decades cancer researchers have devoted significant time, energy, and resources to elucidating at the molecular level how misregulation of cellular signaling – especially the role of kinases – results in tumor formation. The efforts have produced some notable successes, including the launch of medicines such as Novartis AG's Gleevec (imatinib), AstraZeneca PLC's Iressa (gefitinib) , and Tarceva (erlotinib) from OSI Pharmaceuticals LLC (now a division of Astellas Pharma Inc.[See Deal]) and Roche. But despite significant advances, such drugs are far from a cure-all, with tumor cells finding work-arounds that allow them to survive and proliferate even in their presence.

As drug companies continue to search for promising new therapies that can be used in combination with kinase inhibitors, a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.